Non-Consolidated Financial Results (Japanese GAAP)
for the Nine Months Ended September 30, 2026

November 10, 2026

Company Name: Chiome Bioscience Inc. Tokyo Stock Exchange
Stock Code: 4583 URL https://www.chiome.co.jp
Representative: Masamichi Koike, President & CEO
Inquiries: Miseri Tanaka, Head of Corporate Division TEL: +81-3-6383-3561
Scheduled dividend payment commencement date: —
Supplementary materials prepared for the quarterly financial results: Yes
Holding of the quarterly financial results explanatory meeting: No

(Amounts of less than one million yen are rounded down)

1. Financial Results for the Nine Months Ended September 30, 2026 (January 1, 2026 to September 30, 2026)

(1) Operating Results (Cumulative)

(% figures are the increase / (decrease) compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended Sep. 30, 2026	406	10.0	(736)	—	(737)	—	(739)	—
Nine months ended Sep. 30, 2025	369	(12.5)	(805)	—	(807)	—	(800)	—

	Net Income per Share	Diluted Net Income per Share
	Yen	Yen
Nine months ended Sep. 30, 2026	(9.76)	—
Nine months ended Sep. 30, 2025	(11.79)	—

Notes: Despite the existence of shares with a dilutive effect, "Diluted Net Income per Share" is not stated because Chiome incurred a loss for each respective period.

(2) Financial Position

	Total Assets	Net Assets	Equity Ratio
	Million yen	Million yen	%
As of Sep. 30, 2026	1,833	1,503	82.0
As of Dec. 31, 2025	1,727	1,122	64.1

(Reference) Equity As of Sep. 30, 2026: 1,503 million yen As of Dec. 31, 2025: 1,107 million yen

2. Dividends

	Annual Dividends				
	1Q-End	2Q-End	3Q-End	FY-End	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal Year Ending Dec. 31, 2025	—	0.00	—	0.00	0.00
Fiscal Year Ending Dec. 31, 2026	—	0.00	—		
Fiscal Year Ending Dec. 31, 2026 (Forecast)				0.00	0.00

Note: Revision to the most recently announced dividend forecast: No

3. Forecasts of Financial Results for the Fiscal Year Ending December 31, 2026 (January 1, 2026 to December 31, 2026)

As it is difficult to provide reasonable estimates for Drug Discovery and Development Business at present, Chiome discloses only business forecasts for Drug Discovery Support Business (net sales of ¥600 million). There is no revision to the most recently announced forecasts of financial results.

[Notes]

(1) Application of Special Accounting Practices in the Preparation of Quarterly Financial Statements: No

(2) Changes in Accounting Policies, Changes in Accounting Estimates, and Retrospective Restatements
- 1) Changes in accounting policies in line with revisions to accounting and other standards: No
- 2) Changes in accounting policies other than 1) above: No
- 3) Changes in accounting estimates: No
- 4) Retrospective restatements: No

(3) Number of Shares Issued (Common Stock)

1) Number of shares issued as of the end of the period (including treasury stock)	As of Sep. 30, 2026	81,863,700 shares	As of Dec. 31, 2025	68,453,800 shares
2) Number of treasury stock as of the end of the period	As of Sep. 30, 2026	22,819 shares	As of Dec. 31, 2025	12,149 shares
3) Average number of shares for the period (cumulative total for the period)	Nine months ended Sep. 30, 2026	75,784,769 shares	Nine months ended Sep. 30, 2025	67,851,597 shares

* Review of the attached quarterly financial statements by certified public accountants or an auditing firm: No

* Explanation Concerning the Proper Use of Financial Results Forecasts and Other Relevant Specific Items

Forward-looking statements including forecasts of financial results contained in this report are based on management's assumptions and beliefs that are determined to be reasonable in light of currently available information. Chiome cautions readers that due to a variety of factors actual results may differ materially from forecasts. For the assumptions that underpin financial results forecasts as well as other related items, please refer to the "1. Qualitative Information Regarding Quarterly Financial Results (3) Explanation of Forward-Looking Statements including Forecasts of Financial Results" on page 5 of this report.

Contents

1. Qualitative Information Regarding Quarterly Financial Results 2
   (1) Overview of Operating Results in this quarter 2
   (2) Overview of Financial Position in this quarter 5
   (3) Explanation of Forward-Looking Statements including Forecasts of Financial Results 5
2. Quarterly Financial Statements 6
   (1) Quarterly Balance Sheets 6
   (2) Quarterly Statements of Income 8
   (3) Notes Concerning Quarterly Financial Statements 9
   (Notes regarding going concern assumptions) 9
   (Notes regarding substantial changes in shareholders' equity) 9
   (Notes regarding Cash Flows) 9
   (Segment information) 9
   (Important subsequent events) 10

1. Qualitative Information Regarding Quarterly Financial Results

(1) Overview of Operating Results

The Company operates a drug discovery business, mainly developing antibody drugs for areas with high unmet needs, utilizing its antibody generation technology and drug discovery expertise. The Company also operates a drug discovery support business that offers drug discovery technologies and capabilities based on experience and know-how, such as antibody generation and protein expression/purification to pharmaceutical companies and academic institutions. In addition, by leveraging manufacturing capabilities, one of its strengths, the Company also operates the Integrated Drug Discovery (IDD) business. The IDD business is expected to contribute to Japan's drug discovery ecosystem. By playing a role in the drug discovery ecosystem through our manufacturing capabilities, thereby supporting the Company's business growth.

An overview of the Company's business activities for the nine-month period is as follows.

In the drug discovery business, Phase I clinical studies are underway for CBA-1535 and CBA-1205; both are house developed therapeutic antibodies for cancer. For CBA-1205, currently evaluation of safety and initial efficacy of CBA-1205 for pediatric cancer patients is underway. Dosing has been completed in patients with melanoma and hepatocellular carcinoma, and data analysis is underway. For CBA-1535, a multispecific antibody targeting cancer, the Company is evaluating its safety in patients with solid tumors. Dosing to the last cohort in the first part of the study is in progress. For other drug discovery pipeline products, the Company continues introductions, scientific validations and discussions with potential out-licensing partners at business conferences and other events are in progress to secure contracts.

In the drug discovery support business, while focusing on maintaining strong relationships with existing major domestic pharmaceutical companies engaged in antibody drug discovery, the Company continues to promote activities to stabilize its revenue base during the interim period.

In the IDD business launched in the previous fiscal year, which is a platform-based initiative for antibody drug discovery, we are progressing biosimilar related business with Alfresa Holdings Corporation (Alfresa Holdings) and Kidswell Bio Corporation (Kidswell) and are steadily advancing the joint development of new cell line development for biosimilars. Furthermore, the Company is exploring collaboration opportunities with pharmaceutical companies in Japan and abroad, aiming for new biosimilar discoveries as well as out-licensing opportunities for biosimilars under development. Other than biosimilars, discussions are in progress with potential business partners mainly with start-up companies with the aim of generating new drug-related projects by leveraging the Company's DoppeLib® (*) technology or Chemistry, Manufacturing and Control (CMC) capabilities. The Company entered into a joint research agreement with FRONTEO, Inc. (FRONTEO) in September 2026 to create bispecific antibody drugs using artificial intelligence (AI) technologies. This joint research aims to create new antibody drugs candidates, as well as out-licensing them by directly linking hypothesis validation using KIBIT by FRONTEO with antibody generation using the Company's proprietary DoppeLib® technology.

The Company's performance during the nine-month period is as follows: net sales of ¥406,975 thousand (an increase of ¥37,159 thousand year on year), R&D expenses of ¥561,423 thousand (a decrease of ¥24,774 thousand year on year), operating loss of ¥736,663 thousand (operating loss of ¥805,347 thousand in the same period last year), ordinary loss of ¥737,211 thousand (ordinary loss of ¥807,411 thousand in the same period last year), and interim net loss of ¥739,641 thousand (interim net loss of ¥800,253 thousand year on year). R&D expenses, particularly clinical development-related expenses, decreased compared with the same period last year, contributing to reduction in operating loss, ordinary loss and interim net loss year on year.

An overview of the Company's business activities for the nine-month period by segment is as follows.

・Drug Discovery Business

➢ Drug Discovery Pipeline (out-licensed products)

PFKR is a humanized antibody targeting CX3CR1, a G protein-coupled receptor (GPCR). It is a therapeutic antibody candidate identified through a joint research collaboration between our company and the National Center of Neurology and Psychiatry (NCNP). In November 2024, the Company entered into license agreement with Asahi Kasei Therapeutics Corporation (formerly Asahi Kasei Pharma Corporation), which is currently preparing for the initiation of preclinical studies. Under the agreement, milestones in line with development progress were set. The Company will receive milestone payments specified in the agreement whenever a milestone is achieved.

➢ Drug Discovery Pipeline (In-house programs, out-licensing candidates)

For CBA-1205, the Company is conducting the second part of the Phase I clinical study in Japan. The primary objective of the study is to evaluate safety and tolerability of CBA-1205 in cancer patients. The first part of the study is for patients with solid tumors, and the second part is for patients with melanoma, hepatocellular carcinoma and pediatric cancers. Patient enrollment for the first part has been completed, and CBA-1205 demonstrated a favorable safety profile at doses up to 30mg/kg. Notably, we have confirmed a case in which a melanoma patient enrolled in the first part has maintained stable disease (SD) assessment with tumor shrinkage for more than 4 years. In the second part, patient enrollment for melanoma and hepatocellular carcinoma has been completed and evaluation of patients who continued treatment and analysis of the data are currently ongoing. As in the first part, CBA-1205 demonstrated a favorable safety profile. In a patient with confirmed expression of DLK1, tumour shrinkage of more than 30% (PR) has been observed. Currently patient enrollment for pediatric cancers is in progress. The evaluation of safety and tolerability of pediatric cancer patients with confirmed expression of DLK1 at screening is ongoing. In the screening test up to date, high frequency of DLK1 expression has been observed. Safety evaluation of the initial dose cohort has been completed, and that of the high dose cohort is currently underway.

A Phase I clinical study of CA-1535 in patients with solid tumors is also underway in Japan. At present, evaluation for the safety and tolerability of CBA-1535 as a single agent is in progress and no adverse events raising development concerns have been observed. From June 2026, dosing to the final cohort is in progress in the first part of the study. For CBA-1535, taking competitors' development activities into account, the Company will not conduct the combine part and prioritize initiatives of out-licensing activities utilizing the clinical data from the single agent study.

PTRY is a Tribody® (*) antibody and is expected to add immune checkpoint inhibitory function on the T-cell engager function of CBA-1535. Its initial evaluations using animal models have shown strong anti-tumor effects. For the development of this product, we have decided to prioritize out-licensing to other pharmaceutical companies who can enter commercialization and clinical development rather than carrying out early clinical development by ourselves. This is because we can expect licensing out in pre-clinical stages, depending on the development status of CBA-1535.

For PCDC, we are conducting out-licensing activities for PCDC, a humanized anti-CDCP2 antibody, with a focus on antibody drug conjugate (ADC) applications. Amid growing global interest in ADCs, we are promoting out-licensing activities with pharmaceutical companies that own ADC technologies.

In addition, the Company is pursuing out-licensing activities for multiple drug discovery projects in the exploratory phase, including PXLR, while also advancing collaborative research on mRNA x Tribody®, to generate new pipeline candidates through in-house research as well as research collaboration with academic institutions.

➢ IDD Business

The company has been promoting the creation of drug seeds and making them into intellectual property to expand

our pipeline and explorer out-licensing opportunities. In addition, it aims to enhance profitability through this IDD business that utilizes its antibody drug discovery technology and know-how. The Company focused on establishing new collaborations with pharmaceutical and startup companies in drug discovery research and/or biosimilar development. During the nine-month period, through business alliance with Axcelead Drug Discovery Partners Inc., a new project has started. The Company's key technology for future IDD business, proprietary bispecific antibody generation technology called DoppeLib®, is a technology to generate and screen numerous antibody combinations efficiently and comprehensively. It is a high-throughput screening technology searching for promising bispecific antibody candidates. The technology has the advantage of efficiently identifying promising antibody candidates from a vast number of antibody combinations. The Company is pursuing joint research and other forms of collaboration opportunities with pharmaceutical companies and continuing efforts to introduce the technology. In September 2026, the Company entered into joint research agreement with FRONTEO, and the research of linking their novel target discovery by AI drug discovery support services called Drug Discovery AI Factory (DDAIF) and our antibody candidate generation and validation by DoppeLib® has started. By conducting joint research on several themes, the Company aims to create bispecific antibody drug candidates during the fiscal year 2027 and for antibody drug candidates acquired through the research, the Company is aiming at joint research and out-licensing to pharmaceutical companies promptly. The knowledge and results obtained through the joint research can be used in our IDD business and are expected to contribute to strengthening its medium-to long-term competitiveness and profitability.

As a result of the above, the Company's performance in the drug discovery business during the nine-month period is as follows: R&D expenses amounted to ¥561,423 thousand due to the progress of clinical development (a decrease of ¥24,774 thousand year on year), and segment loss of ¥561,423 thousand (segment loss of the same period last year was ¥586,198 thousand).

・Drug Discovery Support Business

The drug discovery support business contributes to the company's stable earnings. It provides research support services by undertaking antibody production utilizing its proprietary antibody generation platform, and protein preparation works mainly utilizing its protein purification technologies. The Company supports biopharmaceutical research mainly for major domestic pharmaceutical companies such as Ono Pharmaceutical Col, Ltd. and Chugai Pharmaceutical Co., Ltd. The Company's service capabilities are highly recognized by its client companies. Efforts to stabilize the revenue base are ongoing. The revenue from joint development on cell line constructions for biosimilars with Alfresa Holdings and Kidswell is recognized as revenue for this business.

The result for the nine-month period in the drug discovery support business are as follows: sales from research support for pharmaceutical companies decreased, but sales-related to biosimilars increased, resulted in net sales of ¥406,975 thousand (an increase of ¥37,159 thousand year on year), segment profit of ¥235,770 thousand (an increase of ¥31,604 thousand year on year), and a segment margin of 57.9% (target 50%).

(*) DoppeLib is registered as a trademark in 4 countries including Japan and USA, while Tribody is registered in Japan.

(2) Overview of Financial Position

(Assets)

Total assets at the end of the nine-month period amounted to ¥1,833,303 thousand, a increase of ¥105,798 thousand from the end of the previous fiscal year. This was mainly due to the increase in cash on hand and in banks.

(Liabilities)

Total liabilities at the end of the nine-month period amounted to ¥329,797 thousand, a decrease of ¥275,643 thousand from the end of the previous fiscal year. This was mainly due to a decrease in corporate bonds

(Net assets)

Total net assets at the end of the nine-months period amounted to ¥1,503,506 thousand, a increase of ¥381,441 thousand. This was mainly due to increases in share capital and capital reserve from the exercise of stock acquisition rights.

(3) Explanation of Forward-Looking Statements including Financial Forecasts

There are no changes to the financial results forecasts for the year ending December 31, 2026, announced on February 10, 2026.

The impact of the Middle East situation on the Company's business is expected to be minimal as of now.

2. Quarterly Financial Statements

(1) Quarterly Balance Sheets

Thousand yen

	As of Dec. 31, 2025	As of Sep. 30, 2026
Assets		
Current assets		
Cash on hand and in banks	1,205,026	1,287,038
Accounts receivable	71,996	25,974
Inventories	49,412	83,867
Advance payment-trade	135,015	160,229
Consumption taxes receivable	29,520	24,888
Other current assets	55,726	76,220
Total current assets	1,546,698	1,658,217
Non-current assets		
Property and equipment		
Machinery	250,121	253,975
Accumulated depreciation	(213,781)	(214,364)
Machinery, net	36,340	39,611
Tools and equipment	79,857	77,699
Accumulated depreciation	(79,857)	(77,699)
Tools and equipment, net	0	0
Total property and equipment	36,340	39,611
Investments and other assets		
Lease deposits and others	128,191	128,196
Long-term prepaid expenses	16,274	7,278
Others	0	0
Total investments and other assets	144,465	135,474
Total non-current assets	180,806	175,086
Total assets	1,727,504	1,833,303

Thousand yen

	As of Dec. 31, 2025	As of Sep. 30, 2026
Liabilities		
Current liabilities		
Accounts payable, trade	37,442	31,481
Short-term borrowings	86,700	76,000
Accounts payable, other	82,517	88,648
Accrued expenses	14,555	11,970
Income taxes payable	12,553	18,974
Contract liabilities	130,329	41,004
Deposits received	10,787	5,834
Total Current liabilities	374,885	273,915
Non-current liabilities		
Asset retirement obligations	55,554	55,882
Bonds payable	175,000	—
Total non-current liabilities	230,554	55,882
Total liabilities	605,440	329,797
Net assets		
Shareholders' equity		
Capital stock	1,085,523	1,653,339
Capital reserve	2,025,797	2,593,614
Retained earnings	(2,003,555)	(2,743,197)
Treasury stock	(292)	(310)
Total shareholders' equity	1,107,473	1,503,446
Share acquisition rights	14,591	60
Total net assets	1,122,064	1,503,506
Total liabilities and net assets	1,727,504	1,833,303

(2) Quarterly Statement of Income

(Third Quarter Cumulative)

Thousand yen

	Nine Months Ended Sep. 30, 2025 (Jan. 1, 2025 to Sep. 30, 2025)	Nine Months Ended Sep. 30, 2026 (Jan. 1, 2026 to Sep. 30, 2026)
Net sales	369,815	406,975
Cost of sales	165,648	171,204
Gross profit	204,166	235,770
Selling, general and administrative expenses		
Research and development expenses	586,198	561,423
Other, net	423,315	411,009
Total selling, general and administrative expenses	1,009,513	972,433
Operating loss	(805,347)	(736,663)
Non-operating income		
Interest income	2,332	3,021
Foreign exchange gains	—	1,307
Other, net	142	155
Total non-operating income	2,475	4,484
Non-operating expenses		
Interest expenses	2,899	888
Share issuance expenses	1,635	4,144
Other, net	4	0
Total non-operating expenses	4,539	5,032
Ordinary loss	(807,411)	(737,211)
Extraordinary income		
Gain on reversal of share acquisition rights	9,588	—
Total extraordinary income	9,588	—
Loss before income taxes	(797,823)	(737,211)
Income taxes-current	2,430	2,430
Total income taxes	2,430	2,430
Net loss	(800,253)	(739,641)

(3) Notes Concerning Quarterly Financial Statements

(Notes Regarding Going Concern Assumptions)

Not applicable.

(Notes Regarding Substantial Changes in Shareholders' Equity)

During the third cumulative period, the balance of capital stock and capital reserve increased separately by ¥567,816 thousand mainly due to exercise of the Subscription Rights to Shares. As a result, as of September 30, 2026, the balance of capital stock and capital reserve came to ¥1,653,339 thousand and ¥2,593,614 thousand, respectively.

(Notes to quarterly cash flow statement)

The cash flow statement for the nine months is not present herein. Depreciation and amortization for the nine months are as follows.

(Thousand yen)

	Nine Months Ended Sep. 30, 2025 (Jan. 1, 2025 to Sep. 30, 2025)	Nine Months Ended Sep. 30, 2026 (Jan. 1, 2026 to Sep. 30, 2026)
Depreciation and amortization	1,235	7,667

(Segment information)

The Nine Months Ended September 30, 2025 (January 1, 2025 to September 30, 2025)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	—	126,704	126,704	—	126,704
Goods or services transferred over a period of time	—	243,111	243,111	—	243,111
Revenue from contracts with customers	—	369,815	369,815	—	369,815
Sales to external customers	—	369,815	369,815	—	369,815
Internal sales or exchange between segments	—	—	—	—	—
Total	—	369,815	369,815	—	369,815
Segment income (loss)	(586,198)	204,166	(382,032)	(423,315)	(805,347)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.

(2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.

2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

The Nine Months Ended September 30, 2026 (January 1, 2026 to September 30, 2026)

(Thousand yen)

	Reportable Segments		Total	Adjustments (Note 1)	Amount Recorded on the Balance Sheet (Note 2)
	Drug Discovery and Development Business	Drug Discovery Support Business			
Net sales					
Goods or services transferred at one point of time	—	95,128	95,128	—	95,128
Goods or services transferred over a period of time	—	311,847	311,847	—	311,847
Revenue from contracts with customers	—	406,975	406,975	—	406,975
Sales to external customers	—	406,975	406,975	—	406,975
Internal sales or exchange between segments	—	—	—	—	—
Total	—	406,975	406,975	—	406,975
Segment income (loss)	(561,423)	235,770	(325,653)	(411,009)	(736,663)

Notes:

1. Details regarding adjustments are presented as follows:
   (1) Adjustments to segment income (loss) are selling, general and administrative expenses that relate to areas other than research and development.
   (2) Segment assets are not allocated between segments because all assets of the Company are unified in their generation of cash flows and apply to multiple antibody generation technologies. Accordingly, the amount of total assets recorded on the balance sheet is presented as the adjustment balance.
2. The total amount of segment income (loss) is reconciled with operating loss recorded in the statement of income.

(Important subsequent events)

Not applicable.